Interview with Patrick Aghanian, General Manager, Sanofi Russia
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Address: 125009, Россия, Москва ул. Тверская, дом 22 Бизнес центр ‘Саммит’ 8 этаж,Russia
Tel: +7 495 721 14 00
Web: http://www.sanofi.ru/l/ru/ru/index.jsp
Sanofi is a diversified global healthcare company focused on patients’ needs. Sanofi is a leader in emerging markets and one of the leading pharmaceutical companies in Europe, it is the world leader in human vaccines and animal health. The Group is present in 100 countries on five continents with almost 100,000 employees. Headquarter of the company is located in Paris.
Sanofi Russia has been present in Russia since 1970. Sanofi offers a large portfolio of original medicines, generics and OTC drugs in key therapeutic areas: diabetes, oncology, cardiovascular diseases, CNS diseases, internal medicine and thrombosis.
Vaccine production is one of Sanofi priorities. Sanofi Pasteur, the vaccine division of the Group, is the world leader in human vaccine production and development. Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. In 2008 it started inactivated polio vaccine production in co-operation with M.P. Chumakov Poliomyelitis and Viral Encephalitis Institute of the Russian Academy of Medical Science for the National Vaccination Calendar.
In March 2009 Zentiva, the leader in the generics segment in CEE markets, became a member of the Group.
In 2010 Sanofi acquired a modern insulin factory located in the Orel region. Sanofi-Aventis Vostok is company’s manufacturing facility for production of human insulin and insulin analogs in hi-tech pens in Russia. At this moment installed production lines can provide from 15 to 30 m. units of insulin dosed forms every year. It is planned to reach full capacity and full insulin production cycle (excuding production of active pharmaceutical ingredient, API) in early 2012.
Improvement of treatment of Russian patients is one of the key objectives of Sanofi group. The company supports large-scale national educational programs in all therapeutic areas. Sanofi launched over 190 specialized epilepsy centers (epicenters) fully equipped and operating as training centers for doctors, over 50 atherothrombosis schools (atheroschools) for doctors under support of the National Atherothrombosis Society. Starting from August 2009, the company has been carrying out all-Russia medico-social program “Help for Heart” to support patients who had instable angina (IA) or myocardial infarction (MI).
Starting from autumn 2009, Sanofi has been implementing all-Russia educational program for diabetes patients “Every day is yours” together with the leading Russian endocrinologists.
Starting from 2011 Sanofi Russia implements social program “Chance to life” aimed at improving the quality of life of women at early stages of breast cancer (BC). In the framework of this program Sanofi Russia will support 2000 patients with early stages of breast cancer supplying high quality medicine for up-to-date treatment in 2011. Starting from August 2011 Sanofi Russia together with the Health department of the Orel region and regional oncology center will start implementing breast cancer patients support program in the Orel region. In 2011 the program will cover 230 patients with BC who should receive chemotherapy with highly efficient modern drugs.Charitable activity of Sanofi Russia is consolidated by the program “Give a Smile”. Its aim is to help children from orphanages, to give orphans joy, warmth and smiles through attention and communication. Employees take an active part in the program. The program grew from single charity actions and in 2010 covered all Russian regions.
Sanofi offers a large portfolio of original medicines, generics and OTC drugs in key therapeutic areas: diabetes, oncology, cardiovascular diseases, CNS diseases, internal medicine and thrombosis.
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
